Emtricitabine and tenofovir disoproxil fumarate

Gilead Sciences is advancing lenacapavir, a potential once-yearly injectable HIV prevention drug, directly from Phase I to Phase III trials, bypassing mid-stage studies due to strong early results.

Gilead Sciences has settled a significant patent dispute with ViiV Healthcare, agreeing to pay $1.25 billion plus ongoing royalties on Biktarvy sales until 2027, resolving litigation dating back to 2018.

The recent USAID stop-work order has halted critical HIV research and treatment programs in Nigeria and Uganda, affecting millions of patients who depend on aid-funded antiretroviral therapy.

Recent global data reveals approximately 40 million people are currently living with HIV worldwide, with 1.2 million cases in the United States among individuals over 13 years old.

Researchers in Kenya are advocating for the approval of Cabotegravir and Lenacapavir, two highly effective drugs for HIV prevention, to reduce the country's HIV burden.